pediatric semaglutide Semaglutide: Half of Children on Drug Are No Longer Clinically Obese, Study Finds Obesity rates lead to rise

Healthcare providers should carefully evaluate each patients health history, monitor for side effects, and adjust treatment plans as needed

The relationship between obesity and bone metabolism is paradoxical, as increased mechanical loading is traditionally associated with higher bone mineral density, yet adiposity-driven chronic inflammation and metabolic dysfunction impair bone quality

Sales have been robust enough that the company is expanding the line

Retatrutide is an investigational triple incretin receptor agonist (GLP-1, GIP, and glucagon) not yet approved by the MHRA or EMA

It is licensed as an adjunct to diet and exercise to improve glycaemic control in adults, either as monotherapy when metformin is inappropriate or contraindicated, or in combination with other diabetes medications